Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 5/20 | 0.77 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.77 |
| ▸ | OXTR | P30559 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5738957 | 1.00 | AVPR2 (0.77) | AVPR2AVPR1AOXTR | |
| SCHEMBL5739209 | 0.88 | AVPR2 (0.59) | AVPR2AVPR1AOXTR | |
| SCHEMBL7388286 | 0.87 | AVPR2 (0.58) | AVPR2AVPR1AOXTR | |
| SCHEMBL7335324 | 0.87 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL7368892 | 0.85 | AVPR2 (0.56) | AVPR2AVPR1A | |
| SCHEMBL5738696 | 0.84 | — | — | |
| SCHEMBL5738960 | 0.84 | — | — | |
| SCHEMBL8317862 | 0.84 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL5739732 | 0.84 | AVPR2 (0.54) | AVPR2AVPR1A | |
| Hydrochloric Acid SCHEMBL5739031 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3737233-B1 | GROWTH FACTOR OTIC FORMULATIONS | DOMPE FARM SPA (IT) | 2025-03-19 | — | — | EP | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20230190642-A1 | GROWTH FACTOR OTIC FORMULATIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2023-06-22 | — | — | US | disclosed |
| CN-115869389-A | Growth factor ear preparation | 奥德纳米有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11389534-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190642-A1 | GROWTH FACTOR OTIC FORMULATIONS | AREG, HDGF, NGF | AVPR2 911/4885AVPR1A 968/4885OXTR 145/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | AVPR2 3337/4885AVPR1A 3673/4885OXTR 571/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | AVPR2 1018/4885AVPR1A 1282/4885OXTR 663/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | AVPR2 1018/4885AVPR1A 1282/4885OXTR 663/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | AVPR2 1018/4885AVPR1A 1282/4885OXTR 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.